Resultados de la búsqueda 81-90 of 2829 for Creatine HCl

1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

2. Médicos y departamentos

   Sidawy AN, et al., eds. Lower extremity arterial disease: Decision making and medical treatment. In: Rutherford's Vascular Surgery and Endovascular Therapy.

3. Médicos y departamentos

   Sidawy AN, et al., eds. Lower extremity arterial disease: Decision making and medical treatment. In: Rutherford's Vascular Surgery and Endovascular Therapy.

4. Hematología - Ensayos clínicos - Mayo Clinic

   Although survivorship recommendations have been developed in areas such as lymphoma and stem cell transplant, the long-term effects of CAR-T therapy are unknown ...

5. Hematología - Ensayos clínicos - Mayo Clinic

   This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy ...

6. Hematología - Ensayos clínicos - Mayo Clinic

   Although survivorship recommendations have been developed in areas such as lymphoma and stem cell transplant, the long-term effects of CAR-T therapy are unknown ...

7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

9. Immune checkpoint inhibitors and thyroid dysfunction A case from the endocrine teaching clinics - Mayo Clinic

   ¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?

10. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...